SLC6A3 and Parkinson disease: In contrast, EOPD patients in the present study are associated with a shorter premotor period and faster decline of estimated DAT levels than the LOPD group, suggesting that non-PD risk genetic factors may have a substantial effect on AAO and dopaminergic deterioration.